Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07153939 · ClinicalTrials.gov registry record · NA

Pivotal Study of the Velocity™ pAVF System

A NA study of Chronic Kidney Disease and End Stage Renal Disease (ESRD), sponsored by Venova Medical.

Recruiting
Registry status
NA
Development phase
126
Enrollment target
10
Study locations

NCT07153939 is a NA study of Chronic Kidney Disease and End Stage Renal Disease (ESRD) that is actively recruiting participants, run by Venova Medical. The registered enrollment target is 126 participants, below the 3,206-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (96% lower). The trial reports 10 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07153939, a NA study of Chronic Kidney Disease and End Stage Renal Disease (ESRD), is actively recruiting participants, sponsored by Venova Medical.

RECRUITING
Registry status
NA
Development phase
126 participants
Enrollment target
10
Study locations

Study Summary

This study will evaluate the Velocity Percutaneous Arteriovenous Fistula (pAVF) System, a new minimally invasive method for creating dialysis access. People with kidney failure often require dialysis, which depends on having a reliable arteriovenous fistula (AVF). Traditionally, AVFs are created with surgery, but surgery can involve incisions, longer recovery, and sometimes additional procedures before the AVF can be used. The Velocity System is designed to create an AVF through a small puncture in the skin using a catheter-based approach, without open surgery. This pivotal study will assess how safe the procedure is and how well it works for patients who need dialysis. The study will take place at multiple centers in the United States and will enroll adults with kidney failure who are candidates for fistula creation. Participants will undergo the Velocity procedure and then be followed closely with exams, ultrasounds, and dialysis assessments for up to five years. Taking part is voluntary. Patients may benefit from a less invasive approach to dialysis access, but the main goal is to collect information that could improve future care for people with kidney failure.

Interventions

  • DEVICE Velocity Percutaneous Arteriovenous Fistula

Study Locations (10)

Texas

  • Aqua Research - Houston
  • Humble Vascular Surgical Center - Humble
  • Fresenius Vascular Care San Antonio - San Antonio
  • San Antonio Surgical Center - San Antonio

California

  • West Coast Kidney Institute Concord - Concord
  • Apex Research - Riverside

Florida

  • Vascular and Embolization Specialists - Cocoa
  • Azura Vascular Care Jacksonville - Jacksonville

Alabama

  • Trinity Research Group - Dothan

North Carolina

  • Surgical Specialists of Charlotte - Charlotte

Trial Details

FieldValue
Enrollment Target 126 participants
Start Date 2025-10-21
Est. Completion 2030-09
Phase NA

Sponsor

Venova Medical

2 total trials

What the Registry Record Tells You About NCT07153939

The ClinicalTrials.gov registry entry for NCT07153939 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,206-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (96% lower). The listed sponsor is Venova Medical, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Chronic Kidney Disease appearing as the primary indexed condition, and to 1 intervention - of which Velocity Percutaneous Arteriovenous Fistula is the first listed.

NCT07153939 reports 10 study locations spanning 5 distinct geographic areas - top geographies include Texas, California, Florida.

Frequently Asked Questions

What is clinical trial NCT07153939 about?

NCT07153939 is a clinical study titled "Pivotal Study of the Velocity™ pAVF System". This study will evaluate the Velocity Percutaneous Arteriovenous Fistula (pAVF) System, a new minimally invasive method for creating dialysis access. People with kidney failure often require dialysis, which depends on having a reliable arteriovenous fistula (AVF). Traditionally, AVFs are created wit...

What is the current status of trial NCT07153939?

This trial is currently recruiting. It is a NA study. The enrollment target is 126 participants. The study started on 2025-10-21. Estimated completion is 2030-09.

What conditions does trial NCT07153939 study?

This clinical trial studies the following conditions: Chronic Kidney Disease, End Stage Renal Disease (ESRD), Arteriovenous Fistula, Hemodialysis Access.

What interventions are being tested in trial NCT07153939?

The interventions under investigation include: Velocity Percutaneous Arteriovenous Fistula (DEVICE).

Who is sponsoring clinical trial NCT07153939?

This trial is sponsored by Venova Medical, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07153939 being conducted?

This trial has 10 study locations across Alabama, California, Florida, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Kidney Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.